The FDA signed its rejection of ivonescimab on 13 November and put the letter online five days later. Summit's announcement gave one reason. The letter gives four, and the first is about where the patients were enrolled.
Witfire Elite | Philippines Pharma Watch | Clinical Catalysts | Nerandomilast Philippines Nerandomilast Philippines trial plans now list three hospitals and a target of…
Witfire Elite | Clinical Catalysts | Trial Design Audit RENGEVITY-201 trial dosing has begun, Veloxis says, with the first participant now treated. The Phase…
Witfire Elite · Clinical Catalysts · Trial Design Audit Pulnovo says two U.S. participants have undergone PULSE-LHD procedures at Henry Ford. The registry estimates…
Witfire Elite · Clinical Catalysts · Registry Analysis OX40 atopic dermatitis development is over. Two companies, two mechanisms, 175 days. The press releases said…
Teva's Q2 2026 revenue fell 1%, operating income fell $686M and the shares rose 8.6%. All three follow from one subtraction the release never performs: US generics lost $301M in the quarter, and three branded products added $306M.
Witfire Elite · Litigation Risk Brief · Product Liability Johnson & Johnson won a causation ruling. One week later it settled anyway. Understanding why…